论文部分内容阅读
目的:研究艾塞那肽治疗对2型糖尿病患者缓解期的影响。方法:选择2009年11月-2010年10月我院内分泌科收治的57例2型糖尿病患者为研究对象,按照病程、体重指数、空腹餐后C肽、血脂、原有治疗方案一一配对分成艾塞那肽组(n=31)与对照组(n=26)。共治疗3个月,每月随访1次,检测血糖、糖化血红蛋白(HbA1c)、C肽、胰岛素,治疗前与治疗3个月后行72h动态血糖监测、静脉葡萄糖耐量试验。结果:艾塞那肽治疗3个月,16.13%(n=5)的2型糖尿病患者出现缓解期,与对照组比较差异有统计学意义(P<0.05);与治疗前比较,艾塞那肽治疗3个月的空腹血糖、餐后血糖、HbA1c下降,高血糖及低血糖所占时间比下降,差异有统计学意义(P<0.05)。结论:艾塞那肽治疗可促进2型糖尿病患者出现缓解期。
Objective: To study the effect of exenatide on remission in type 2 diabetic patients. Methods: From November 2009 to October 2010, 57 cases of type 2 diabetes mellitus admitted to Department of Endocrinology of our hospital were divided into three groups according to the course of disease, body mass index, fasting postprandial C-peptide, blood lipid and the original treatment plan Exenatide group (n = 31) and control group (n = 26). A total of 3 months of treatment were followed up once a month. Blood glucose, HbA1c, C-peptide and insulin were measured. Dynamic blood glucose monitoring and venous glucose tolerance test were performed 72 hours after treatment and 3 months after treatment. Results: There was a significant difference in remission between type 2 diabetic patients treated with exenatide for 3 months and 16.13% (n = 5), which was significantly different from the control group (P <0.05). Compared with pretreatment, The fasting blood glucose, postprandial blood glucose, HbA1c, hyperglycemia and hypoglycemia in the three months of treatment decreased significantly (P <0.05). Conclusion: Exenatide treatment can promote remission in type 2 diabetic patients.